Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate And Cytosolic Creatine Kinase: Biochemical Mechanisms, Therapeutic Applications, And Advanced Research Perspectives

NOV 17, 202658 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate (CP) and Cytosolic Creatine Kinase (CK) constitute a fundamental bioenergetic system responsible for rapid ATP regeneration in tissues with high and fluctuating energy demands, including skeletal muscle, cardiac muscle, brain, and retina. This creatine kinase/creatine phosphate (CK/CP) system operates through reversible phosphoryl transfer reactions, enabling efficient temporal and spatial energy buffering within cells 2. The cytosolic isoforms of creatine kinase—particularly CK-MM (muscle-type) and CK-MB (cardiac-type)—play critical roles in cellular energy homeostasis and serve as important clinical biomarkers for tissue damage 1,7. Recent advances have expanded the therapeutic potential of exogenous CP and CK administration beyond traditional diagnostic applications, encompassing treatment strategies for atherosclerosis, metabolic disorders, neurodegenerative diseases, and ischemic conditions 1,2,8.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Creatine Phosphate And Cytosolic Creatine Kinase

Creatine Phosphate: Chemical Structure And Energetic Properties

Creatine phosphate (N-phosphocreatine, phosphocreatine) is a high-energy phosphagen compound with the molecular formula C₄H₁₀N₃O₅P and a molecular weight of approximately 211.11 g/mol. The molecule contains a guanidinium group linked to an N-methyl glycine moiety, with a phosphate group attached to the nitrogen atom via a high-energy phosphoramidate bond 2. This bond possesses a standard free energy of hydrolysis (ΔG°') of approximately -43.1 kJ/mol at pH 7.4 and 25°C, which is significantly higher than that of ATP (-30.5 kJ/mol), making CP an efficient energy reservoir 1,7.

CP exists predominantly in its anionic form at physiological pH (7.2-7.4), with a pKa of approximately 4.5 for the phosphate group 4. The compound demonstrates excellent aqueous solubility, typically exceeding 50 mg/mL at neutral pH, and exhibits stability in buffered solutions when stored at 2-8°C 5. Commercial preparations of creatine phosphate are commonly supplied as the disodium tetrahydrate salt (Na₂CP·4H₂O), which provides enhanced stability during storage and facilitates accurate formulation in biochemical assays 4,10.

The reversible nature of the CP-ATP interconversion reaction is central to cellular bioenergetics. At physiological pH 7.4, the equilibrium of the creatine kinase-catalyzed reaction (CP + ADP ⇌ Creatine + ATP) is shifted toward ATP formation, with an equilibrium constant (Keq) of approximately 160 1,7. This thermodynamic favorability enables rapid ATP regeneration during periods of high energy demand, maintaining ATP/ADP ratios that support optimal cellular function.

Cytosolic Creatine Kinase Isoenzymes: Structure And Catalytic Mechanism

Creatine kinase exists in multiple isoenzyme forms, each exhibiting tissue-specific expression patterns and distinct subcellular localizations 2,18. The cytosolic isoforms are dimeric proteins composed of two subunit types: M (muscle) and B (brain), which combine to form three major isoenzymes:

  • CK-MM: The predominant isoform in skeletal muscle, comprising approximately 98-99% of total CK activity in mature skeletal myocytes. CK-MM has a molecular weight of approximately 86 kDa and exhibits optimal activity at pH 6.8-7.2 1,15.
  • CK-MB: The cardiac-specific isoform, constituting 15-40% of total CK activity in myocardial tissue. CK-MB serves as a critical biomarker for myocardial infarction, with serum levels rising within 4-6 hours post-infarction and peaking at 12-24 hours 1,7.
  • CK-BB: The brain-type isoform, predominantly expressed in neural tissue, smooth muscle, and certain epithelial cells. CK-BB represents the primary cytosolic CK form in the central nervous system 1,2.

The catalytic mechanism of creatine kinase involves a sequential ordered bi-bi reaction mechanism, wherein substrates bind and products are released in a defined sequence 2,7. The enzyme requires divalent metal ions (Mg²⁺ or Mn²⁺) as cofactors, which coordinate with the β- and γ-phosphate groups of ATP/ADP to form catalytically competent metal-nucleotide complexes 4,16. Kinetic studies have established Km values for CP ranging from 1-5 mM and for ADP from 0.1-0.5 mM under physiological conditions, indicating high substrate affinity 7,18.

Structural analyses reveal that the active site of creatine kinase contains critical residues that facilitate phosphoryl transfer through a direct in-line transfer mechanism 2. Thiol-containing residues, particularly cysteine residues near the active site, are essential for catalytic activity and are susceptible to oxidative inactivation, necessitating the inclusion of thiol-protecting agents (e.g., N-acetylcysteine, dithiothreitol) in biochemical assays and therapeutic formulations 4,5,9.

Biochemical Functions And Cellular Energy Regulation By The Creatine Kinase/Creatine Phosphate System

Energy Buffering And Temporal ATP Homeostasis

The CK/CP system functions as a temporal energy buffer, maintaining stable ATP concentrations during transient periods of high energy demand 2,8. In skeletal muscle during intense contraction, ATP consumption rates can increase 100-fold within milliseconds. Under these conditions, the CK reaction rapidly regenerates ATP from CP, preventing significant ATP depletion and maintaining the ATP/ADP ratio above 10:1, which is critical for sustaining contractile function and preventing cellular injury 1,7.

Quantitative studies in isolated muscle preparations have demonstrated that CP stores can sustain maximal ATP turnover rates for 5-10 seconds before significant depletion occurs 2. The total creatine pool (CP + free creatine) in skeletal muscle typically ranges from 120-140 mmol/kg dry weight, with the CP fraction representing 60-70% of this pool at rest 7,18. During high-intensity exercise, CP levels can decrease by 50-60% within 10 seconds, while ATP levels remain relatively stable (declining by only 10-20%), illustrating the buffering capacity of the system 2.

Spatial Energy Distribution And Subcellular Compartmentalization

Beyond temporal buffering, the CK/CP system facilitates spatial energy distribution through the "phosphocreatine shuttle" or "creatine kinase circuit" 2,8. This model proposes that mitochondrial CK isoforms (located in the intermembrane space) generate CP using mitochondrially-produced ATP, and this CP then diffuses to cytosolic sites of ATP consumption, where cytosolic CK isoforms regenerate ATP locally 2. This mechanism is particularly important in cardiomyocytes and neurons, where ATP consumption sites (e.g., myofibrils, ion pumps) may be spatially distant from mitochondria.

Experimental evidence supporting this model includes:

  • Differential localization of CK isoforms: Mitochondrial CK (mtCK) is bound to the outer surface of the inner mitochondrial membrane, while cytosolic CK-MM and CK-MB are associated with myofibrils, sarcoplasmic reticulum, and plasma membrane 2.
  • Kinetic advantages: CP diffuses approximately 1.4 times faster than ATP in cytoplasm due to its smaller size and lower charge, enabling more efficient energy transfer over cellular distances 2,7.
  • Functional coupling: Studies using CK knockout mice demonstrate impaired contractile function and altered calcium handling, consistent with disrupted spatial energy distribution 2.

Regulation Of Ion Transport And Signal Transduction

The CK/CP system influences cellular signaling pathways through multiple mechanisms 1,2. ATP generated by the CK reaction serves as a substrate for adenylyl cyclase, which produces cyclic AMP (cAMP), a critical second messenger regulating protein kinase A (PKA) signaling cascades 1. Elevated cAMP levels modulate numerous cellular processes, including:

  • Activation of PKA-dependent phosphorylation cascades affecting metabolism, gene transcription, and ion channel activity 1.
  • Regulation of calcium homeostasis through phosphorylation of calcium-handling proteins (e.g., phospholamban, ryanodine receptors) 2.
  • Modulation of vascular tone and endothelial function through effects on nitric oxide synthase and smooth muscle contractility 1.

Additionally, the CK/CP system directly influences ion transport by maintaining local ATP concentrations near ATP-dependent ion pumps (Na⁺/K⁺-ATPase, Ca²⁺-ATPase, H⁺-ATPase) 2,7. Disruption of CK function impairs ion homeostasis, leading to cellular dysfunction and increased susceptibility to ischemic injury 8.

Analytical Methods And Diagnostic Applications Of Creatine Kinase Measurement

Enzymatic Assay Principles And Coupled Enzyme Systems

Measurement of CK activity in biological samples (serum, plasma, tissue homogenates) is essential for clinical diagnosis and research applications 4,7,10. The most widely employed methods utilize coupled enzyme systems that link CK activity to the production or consumption of spectrophotometrically detectable species 7,18.

The standard coupled enzyme assay for CK involves the following reaction sequence 7,10,18:

  1. CK reaction: CP + ADP → Creatine + ATP (catalyzed by CK in the sample)
  2. Hexokinase (HK) reaction: ATP + Glucose → ADP + Glucose-6-phosphate
  3. Glucose-6-phosphate dehydrogenase (G6PDH) reaction: Glucose-6-phosphate + NADP⁺ → 6-Phosphogluconate + NADPH + H⁺

The rate of NADPH formation, monitored by absorbance increase at 340 nm, is directly proportional to CK activity 7,10. Optimal assay conditions include:

  • Buffer: 50-100 mM MOPSO or imidazole, pH 6.5-7.0 4,10
  • Creatine phosphate: 15-30 mM 4,5,10
  • ADP: 2-5 mM 4,10
  • Glucose: 20 mM 10,18
  • Hexokinase: 6,000-7,500 IU/L 4,10
  • G6PDH: 6,000-7,500 IU/L 4,10
  • NADP⁺: 2-4 mM 4,10
  • Magnesium acetate: 10-20 mM 4,10
  • N-acetylcysteine or dithiothreitol: 10-20 mM (CK activator and thiol protectant) 4,5,9
  • Adenosine monophosphate (AMP): 5 mM (adenylate kinase inhibitor) 4,9
  • Diadenosine pentaphosphate (Ap₅A): 10-50 μM (adenylate kinase inhibitor) 9

Alternative coupled enzyme systems have been developed to address limitations of the HK/G6PDH method, including:

  • Phosphoglycerate kinase (PGK)/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) system: This approach offers improved reagent stability and reduced interference from glutathione reductase present in some samples 18. The reaction sequence involves PGK-catalyzed conversion of ATP and 3-phosphoglycerate to ADP and 1,3-bisphosphoglycerate, followed by GAPDH-catalyzed reduction of 1,3-bisphosphoglycerate using NADH, which is monitored at 340 nm 18.

  • Luciferase-based bioluminescent assay: This highly sensitive method employs firefly luciferase to detect ATP generated by the CK reaction 6,9. The assay includes CK-M-specific antibodies to selectively inhibit CK-MM, enabling specific measurement of CK-B subunit activity 6. Optimal conditions include pH 5.8-7.5, 1-10 mM AMP, and at least 50 units of luciferase per test, with diadenosine pentaphosphate (10-50 μM) to inhibit adenylate kinase 9.

Isoenzyme Separation And Clinical Significance

Differentiation of CK isoenzymes is critical for accurate diagnosis of tissue-specific injury 1,4,15. Electrophoretic separation remains a gold standard method, utilizing agarose gel or cellulose acetate membranes to resolve CK-MM, CK-MB, and CK-BB based on charge differences 4. Following electrophoresis, CK isoenzymes are visualized using the coupled enzyme reagent described above, with NADPH fluorescence or tetrazolium salt reduction producing detectable bands 4,11.

Improved electrophoretic reagents incorporate phosphogluconate dehydrogenase (decarboxylating) at 500-3,000 IU/L to enhance sensitivity and reduce background interference 4. Optimal reagent composition includes 15 mM creatine phosphate, 4 mM ADP, 20 mM glucose, 6,500 IU/L hexokinase, 7,500 IU/L G6PDH, 20 mM N-acetylcysteine, 15 mM magnesium acetate, 5 mM AMP, 4 mM NADP⁺, and 1,500 IU/L phosphogluconate dehydrogenase (decarboxylating) in MOPSO buffer (pH 6.5-7.0) 4.

Immunoinhibition assays provide an alternative approach for CK-MB quantification 15. These methods employ antibodies specific for the CK-M subunit to inhibit CK-MM and the M subunit of CK-MB, allowing measurement of residual CK-B activity, which is then used to calculate CK-MB concentration 15. Metal ion-based selective inhibition has also been explored, with aluminum ions (Al³⁺) preferentially inhibiting CK-MB while activating or minimally affecting CK-MM, enabling differential measurement in human serum 15.

Clinical reference ranges and diagnostic thresholds for CK isoenzymes include:

  • Total CK: 30-200 IU/L (males), 20-180 IU/L (females) at 37°C 7
  • CK-MB: <5% of total CK activity; absolute values >10-25 IU/L suggest myocardial injury 1,7
  • CK-MB elevation kinetics: Rise within 4-6 hours post-myocardial infarction, peak at 12-24 hours, return to baseline by 48-72 hours 1,7
  • CK-MM elevation: Indicates skeletal muscle damage (trauma, rhabdomyolysis, muscular dystrophy); levels can exceed 10,000 IU/L in severe cases 1,7

Therapeutic Applications Of Exogenous Creatine Phosphate And Creatine Kinase

Treatment Of Atherosclerosis And Cardiovascular Disease

A novel therapeutic approach involves combined administration of exogenous CP and CPK for treatment of atherosclerotic plaques 1. The rationale is based on the hypothesis that atherosclerotic plaques contain dormant or energy-depleted enzymes (e.g., lipoprotein lipase, cholesterol esterase) that, when reactivated by local ATP provision, can mobilize lipid deposits and promote plaque regression 1.

The proposed mechanism involves:

  1. Energy delivery: Exogenous CP and CPK enter the plaque microenvironment and catalyze local ATP generation from endogenous ADP 1.
  2. Enzyme reactivation: Elevated ATP levels activate plaque-resident enzymes, including those involved
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
ARTCELL INVEST LTD.Treatment of atherosclerotic plaques in arterial walls, cardiovascular disease management, and therapeutic intervention for patients with lipid-rich vascular deposits requiring enzymatic plaque regression.CP-CPK Atherosclerosis TherapyCombined exogenous creatine phosphate and creatine phosphokinase provide localized ATP generation to reactivate plaque-resident enzymes, enabling lipolytic effects on triglyceride-rich lipoproteins and cholesterol mobilization from atherosclerotic plaques without direct negative inotropic effects.
DANA-FARBER CANCER INSTITUTE INC.Prevention and treatment of metabolic disorders including hyperglycemia, insulin-dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, and diabetes-related complications in patients with glucose metabolic dysregulation.Creatine Analogue Metabolic TherapyCreatine phosphate and cyclocreatine modulate the creatine kinase/creatine phosphate energy system to regulate glucose metabolism, improving insulin sensitivity and glucose homeostasis through enhanced cellular ATP regeneration and cAMP-mediated signaling cascades.
BECKMAN INSTRUMENTS INC.Clinical diagnostic laboratories for differential diagnosis of tissue-specific injuries including myocardial infarction (CK-MB elevation), skeletal muscle damage (CK-MM), and neurological conditions, enabling accurate biomarker-based disease detection.CK Isoenzyme Electrophoresis ReagentOptimized reagent containing 15mM creatine phosphate, coupled enzymes (hexokinase 6500 IU/L, G6PDH 7500 IU/L), phosphogluconate dehydrogenase (1500 IU/L), and N-acetylcysteine (20mM) enables enhanced sensitivity and reduced background interference for accurate CK-MM, CK-MB, and CK-BB isoenzyme separation and quantification.
ROCHE DIAGNOSTICS GMBHClinical chemistry analyzers and diagnostic laboratories requiring robust, stable creatine kinase activity measurement in serum and plasma samples for cardiovascular and muscular disease diagnosis with extended reagent shelf-life.Alternative Hexose CK Assay SystemNovel coupled enzyme method utilizing hexokinase with alternative hexose substrates and hexose-6-phosphate dehydrogenases (other than G6PDH) or isomerization pathways, providing improved reagent stability and reduced interference from endogenous glutathione reductase in biological samples.
MITSUBISHI PETROCHEMICAL CO. LTD.Clinical diagnostic applications requiring long-term reagent stability for creatine kinase activity measurement in progressive muscular dystrophy and myocardial infarction diagnosis, particularly in settings where frequent reagent preparation is impractical.PGK-GAPDH CK Measurement SystemPhosphoglycerate kinase and glyceraldehyde-3-phosphate dehydrogenase coupled enzyme system with superior storage stability compared to traditional hexokinase method, eliminating interference from glutathione reductase and enabling accurate CK activity measurement using NADH oxidation monitoring at 340nm.
Reference
  • Combined use of creatine phosphate and creatine phosphokinase for treatment of arteriosclerosis
    PatentWO2010150079A1
    View detail
  • Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
    PatentInactiveUS20050256134A1
    View detail
  • Use of creatine analogues and creatine kinase modulators for the prevention and treatment of glucose metabolic disorders
    PatentInactiveUS20030232793A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png